Logo Image

Dementia

Latest News

pipeline
May 7th 2026
Psychiatry’s Medication Pipeline in Motion

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

frontotemporal dementia granulin mutations PBFT02
April 20th 2026

Ongoing Trial for PBFT02 Shows Improvement of Frontotemporal Dementia With Granulin Mutations

Alzheimer blarcamesine treatment autism
April 14th 2026

Study Links Autism and Alzheimer Disease Through Shared Pathophysiology

Latest Videos

Shorts

Treating Psychosis in Dementia With Zervimesine
1:31
Treating Psychosis in Dementia With Zervimesine
2 months ago
by
Anthony Caggiano, MD, PhD
New Monoclonal Antibodies: Remternetug for Alzheimer Disease
1:46
New Monoclonal Antibodies: Remternetug for Alzheimer Disease
3 months ago
by
Matan Dabora, MD, MBA(+1 more)

CME Content

View More
Southern California Psychiatry Conference
In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!
(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia
Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

View more
Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

View more
Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

View more
Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder
Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

View more
(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia
Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

View more

More News